FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/30/2024
Back to search
Official data from USPTO
LCLNP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
11/30/2024
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
07/18/2022
Registration date
05/28/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
CA
Examiner
DULGER, SUSAN N
Law office
L80
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
NanoVation Therapeutics Inc.
Representatives
Jeffrey A. Smith Millen, White, Zelano & Branigan, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Lipid-based pharmaceuticalslipid-based drug delivery vehicle preparations in the form of lipid formulations that facilitate the delivery of pharmaceuticals for the diagnosistreatment or prevention of diseases and disorderscancerinfectious diseasesgenetic disordersinflammation and immunological disordersfor reducing symptoms associated with aging; nucleic acid-based pharmaceuticalsDNA- and RNA-based pharmaceuticals for the diagnosistreatment or prevention of diseases and disorderscancersinfectious diseasesgenetic disordersinflammation and immunological disorders and for reducing symptoms associated with aging; small molecule pharmaceuticals for use in the diagnosistreatment or prevention of cancerinfectious diseasesgenetic disordersinflammation and immunological disorders and for reducing symptoms associated with aging; protein- and peptide-based pharmaceuticals for use in the diagnosistreatment or prevention of cancerinfectious diseasesgenetic disordersinflammation and immunological disorders and for reducing symptoms associated with aging
Class 42
Pharmaceutical research and development services; pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical formulation development services
Publications
History of USPTO decisions and trademark events.
34 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/10/2024
FIMP
FINAL DISPOSITION PROCESSED
11/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/28/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/28/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/13/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/13/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2024
PUBO
PUBLISHED FOR OPPOSITION
03/12/2024
GPNX
NOTIFICATION PROCESSED BY IB
03/11/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/21/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/21/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/08/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
02/07/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/07/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
02/07/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/08/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2024
RFNT
REFUSAL PROCESSED BY IB
08/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/11/2023
RFRR
REFUSAL PROCESSED BY MPU
07/11/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/03/2023
CNRT
NON-FINAL ACTION WRITTEN
06/02/2023
DOCK
ASSIGNED TO EXAMINER
05/02/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/11/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/14/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/13/2022
Continuous trademark protection
Get notified about every new filing that threatens LCLNP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.